Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Dupixent (dupilumab) is a brand-name subcutaneous injection that’s prescribed for atopic dermatitis, asthma, and more. It works to treat those conditions by blocking proteins that cause ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

In addition, Dupixent is approved to treat the following: corticosteroid-dependent asthma in children ages 6 years and older CRwNP in children ages 12 years and older atopic dermatitis (eczema ...

Dupixent (dupilumab) is available in Japan in a 300 mg dose as a pre-filled syringe or pre-filled pen and is now available ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing ...

Dupixent (dupilumab) is a prescription drug that works to treat certain inflammatory conditions, such as atopic dermatitis, by reducing inflammation signals in your immune system. Your response to ...

In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic ...